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suppression and/or tissue cell sequestration, which somewhat
delayed the diagnosis. Studies have shown that the syndrome
takes between 1 and 8 weeks to develop; in this case the patient
became unwell within a matter of hours. The rapidity of the
onset of the patient’s symptoms mimics the IgE-mediated reac-
tion seen in anaphylaxis; however, the negative mast cell tryp-
tase result precludes this diagnosis.
In summary, we describe a novel, acute severe manifestation of
DRESS syndrome caused by administration of a b-lactam anti-
biotic. The further administration of a b-lactam antibiotic to treat
a presumptive neutropenic sepsis may have exacerbated the
patient’s condition and, had the early recognition of a possible
DRESS syndrome not been made, could easily have resulted in a
case report with a less favourable outcome. A case, nearly, of
‘killing with kindness’ through protocol-driven antimicrobial pre-
scribing, in this case for presumed neutropenic sepsis. This case
may question in part perhaps the broad philosophy of protocol-
driven prescribing and emphasizes the need for better education
regarding the presentation of acute sepsis and its medical mimics,
and the existence of non-anaphylactic acute, severe drug reactions.
The patient has been told to avoid all b-lactam drugs in the
future and that the condition may recur in conjunction with
administration of other classes of drugs.
The patient’s consent for publication of this case report has
been obtained.
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Sir,
Clinical trials with the recommended 2 g daily dose (500 mg four
times a day) of imipenem in febrile neutropenia have reported
success rates of 60–80%.1 Causes of persistent neutropenic fever
often remain unexplained, which results in multiple investigations
and empirical modifications of antimicrobial therapy.2 The
pharmacodynamic parameter predicting the in vivo antibacterial
efficacy of b-lactam antibiotics is the proportion of the dosing
interval during which plasma concentrations are above the MIC
for the causative pathogen (T.MIC). For carbapenems, T.MIC
during 50–60% of the dosing interval is required to achieve bac-
tericidal activity in neutropenic experimental animal models.3 In
life-threatening infections, such as febrile neutropenia, success
rates were significantly higher with T.MIC during 75–100% of the
dosing interval.4 Based on these observations, some experts have
recommended maintaining the trough antibiotic concentrations
above the MIC, e.g. by extending the drug infusion time or by
administering the drug with a continuous infusion.3,5
We retrospectively assessed the association between imipe-
nem plasma concentrations and response to antibacterial therapy
in 29 neutropenic patients (79% acute leukaemias; 86% males;
median age 58 years, range 27–78) with persistent fever for
3 days: 14 microbiologically documented infections (MDIs;
48%); 9 clinically documented infections (CDIs; 31%); and 6
fever of unknown origin (FUO; 21%). Imipenem was prescribed
at the recommended dose for febrile neutropenia adjusted to the
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renal function (median 2 g/day, range 1–4; divided in four infu-
sions over 30 min every 6 h). Results of imipenem plasma
trough concentrations measured during persistent fever by a vali-
dated HPLC-UV method were obtained at a median of 6 days
after start of therapy (range 3–11). Imipenem trough concen-
trations above 1 mg/L [MIC90 for the most frequent pathogens
of febrile neutropenia according to the susceptibility data from
the European Committee on Antimicrobial Susceptibility Testing
(EUCAST); http://www.eucast.org] were targeted.
Median imipenem trough concentrations were 0.9 mg/L
(range 0.25–5). A cause of persistent fever was documented in
16/29 (55%) episodes (6 resistant bacteria, 8 probable/possible
mycoses and 2 non-infectious aetiologies). In 13/29 (45%) epi-
sodes (4 MDIs, 5 CDIs and 4 FUO) the cause of persistent fever
(median duration 6 days, range 3–16) remained unknown.
Imipenem concentrations were interpreted as low according to
the above criteria in eight (62%) of them (median 0.6 mg/L,
range 0.25–1). Imipenem underdosing was considered the prob-
able cause of failure in three cases (no documented alternative
cause and clinical improvement within 3 days after imipenem
dose adjustment in the absence of any concomitant interven-
tion): the clinical characteristics are summarized in Table 1. In
the five remaining cases, the role of imipenem underdosing in
the unexplained persistence of fever could not be assessed
because of concomitant interventions in addition to imipenem
dose adjustment (empirical antifungal therapy and/or vancomy-
cin therapy, three cases), change of antibacterial therapy (one
case) or spontaneous resolution of fever in the absence of any
intervention (one case).
In febrile neutropenic patients, variations in the pharmacoki-
netics of b-lactam antibiotics, such as an increase in the volume
of distribution and/or renal clearance, have been frequently
reported. These modifications result in lower plasma concen-
trations when compared with healthy subjects.6,7 We observed a
high proportion of insufficient imipenem plasma concentrations
in febrile neutropenic patients with persistent fever receiving the
recommended 2 g daily dose. The analysis of clinical data
suggests that imipenem underdosing was the probable cause of
failure in a subgroup of patients not responding to therapy.
The persistence of fever despite broad-spectrum antibacterial
therapy is observed in one-third of febrile neutropenic episodes.
According to the Infectious Diseases Society of America guide-
lines, reassessment of empirical antibacterial therapy is rec-
ommended after 3–5 days of persistent fever; as resistant
bacterial infections or invasive mycoses are suspected, an exten-
sive diagnostic work-up, empirical modifications of antibacterial
therapy and/or addition of antifungal therapy have to be con-
sidered.2 In the majority of cases the cause of persistent fever
cannot be identified and the utility of such interventions remains
unknown. Although changes in pharmacokinetic parameters are
frequently observed in these patients, inappropriate antibiotic
dosing is usually not considered among the possible causes of
failure. The measurement of antibiotic plasma concentrations by
HPLC (or bioassay, as a simple alternative in hospitals without a
clinical pharmacology service) is non-invasive and inexpensive,
and might be easily added to the clinical, microbiological and
radiological reassessment of response to empirical antibacterial
therapy recommended during the time window including
3–5 days of persistent neutropenic fever. Documentation of low
antibiotic blood levels in the absence of another cause of failure
may contribute to optimizing individual management by avoiding T
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unnecessary and expensive investigations and empirical modifi-
cations of therapy. Prospective pharmacodynamic investigations
are needed to confirm the utility of measuring antibiotic plasma
concentrations in persistent febrile neutropenia, which would
justify its implementation in clinical management.
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Sir,
HIV-2 or dual HIV-1/2 infection makes up between 4% and
24% of all HIV infections in West Africa, and dual infection
12% of all infections in Ghana.1 HIV-2 infection progresses to
AIDS more slowly than HIV-1; however, dual infection appears
to progress at a rate similar to that of HIV-1.2 Antiretroviral
therapy (ART) has been widely available in Ghana since 2003,
with good initial results.3 Non-nucleoside reverse transcriptase
inhibitor (NNRTI)-based ART is first-line therapy. In many
centres HIV testing has not routinely been type-specific, so
patients infected with HIV-2 have started ART including
NNRTIs that are ineffective against HIV-2.
To analyse the impact of NNRTI-based ART in dual HIV-1/2
or HIV-2 seropositive individuals in terms of clinical outcomes,
surrogate markers or resistance mutations, we conducted a retro-
spective study of patients attending a large HIV clinic in Ghana
where type-specific HIV testing was not routine. The study was
approved by the Committee on Human Research Publications
and Ethics at KNUST, Kumasi. Patients were tested for HIV-2
seropositivity using the Immunocomb HIV-1&2 Biospot test
(Orgenics, Yavne, Israel). Response to NNRTI-based ART, efa-
virenz/nevirapine with two nucleoside reverse transcriptase
inhibitors (NRTIs), was compared in 57 dual HIV-1/2 seroposi-
tive, 16 HIV-2 seropositive and 197 HIV-1 seropositive patients
who had completed at least 12 months of ART. Clinical and
laboratory data were collected retrospectively at 6 monthly inter-
vals. Changes in patient weight, total CD4 count and HIV viral
load a minimum of 3 months after starting ART were compared.
Mean values for (normally distributed) laboratory data were
compared using t-tests and x2 tests for categorical data.
Baseline characteristics (pre-ART) and responses to ART are
shown in Table 1. There were significantly more females in the
HIV-2-infected groups. Increases in mean CD4 count at 6 and/or
12 months after starting ART were significantly lower in HIV-2
seropositive compared with HIV-1 and dual seropositive
patients, despite starting from higher CD4 counts. Weight gain
was also lower in this group. Samples were available to quantify
HIV-2 and/or HIV-1 viral loads in a proportion of patients
(HIV-2, 63%; dual seropositive, 56%; HIV-1, 22%) after a
median of 14 months of ART. Whilst in the majority of dual ser-
opositive and HIV-1 seropositive patients HIV-1+HIV-2 viral
loads were suppressed on ART, only 19% of the HIV-2 seropo-
sitive patients achieved undetectable HIV-2 viral loads. There
was little difference in the rates of AIDS-defining pathology
between groups. Only one death was recorded, in a HIV-2 sero-
positive patient; however, a number of patients were lost to
follow-up after the first year of ART. In samples from seven
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